

GLAXOSMITHKLINE PLC  
Form 6-K  
October 20, 2009

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending October 2009

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

**Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons**

I give below details of an increase in interests in Ordinary shares in GlaxoSmithKline plc purchased at a price of £12.77 per share on 15 October 2009, and Ordinary share ADRs in GlaxoSmithKline plc purchased at a price of \$39.62 per ADR on 15 October 2009, in respect of the personal holdings of the under-mentioned persons following the re-investment of the dividend paid to shareholders on 8 October 2009.

	<b>Ordinary shares</b>	<b>ADRs</b>
Mr A P Witty	229.07	
Mr J S Heslop	0.01	
Dr M M Slaoui	133.56	
Mrs C E Bruck Slaoui	39.64	
Mr S M Bicknell	71.17	
Mr J M Clarke	139.34	
Mr M Dunoyer	86.27	
Mr E J Gray	152.25	
Mr D Learmouth	41.34	
Mr W C Louv		49.59
Mr D J Phelan		136.73
Dr D Pulman		79.09
Mr D S Redfern	66.05	
Ms C Thomas	50.17	
Mr J R Stéphane	435.92	

The Company was advised of this information on 19 October 2009.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Deputy Company Secretary

20 October 2009

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: October 20, 2009

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc